Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management.

    Asian J Psychiatr 2017 Oct 4;29:106-109. Epub 2017 May 4.
    Professor Psychiatry, Northern Ontario School of Medicine, Laurentian and Lakehead University, Ontario, Canada; Emeritus Professor Psychiatry, Schulich School of Medicine, Western University, Ontario, Canada. Electronic address:
    Neuroleptic Malignant Syndrome (NMS) is a life threatening complication of antipsychotic therapy. It is often assumed to be rare. Observations suggest that rather than overestimating its frequency, we are more likely to underestimate it (Pope et al., 1986). It is a rare but potentially fatal disorder characterized by four principal symptoms. These are mental status changes, muscle rigidity, hyperthermia, and autonomic dysfunction. The diagnosis of NMS often presents a challenge because several medical conditions generate similar symptoms. Although less common now than in the past, thanks to greater awareness, it remains a risk in susceptible patients receiving conventional or atypical neuroleptics. Reducing the risk factors, early recognition of suspected cases, and prompt management can significantly reduce morbidity and mortality of this dangerous condition. Collaboration between psychiatry and other medical specialities may be the key to a successful outcome.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Neuroleptic malignant syndrome. Recognition, prevention and management.
    Drug Saf 1998 Jul;19(1):73-82
    London Health Science Centre, Ontario, Canada.
    Neuroleptic malignant syndrome (NMS) is a rare but potentially lethal form of drug-induced hyperthermia characterised by mental status changes, muscle rigidity, hyperthermia and autonomic dysfunction. Increased awareness and early recognition will lead to prompt management. The diagnosis of NMS presents a challenge because several medical conditions generate similar symptoms. Read More
    [Case report: Neuroleptic malignant syndrome and diagnostic difficulties].
    Encephale 2016 Jun 26;42(3):277-80. Epub 2016 Feb 26.
    Pôle Santé Publique, Pharmacovigilance, CHU Grenoble-Alpes, 38000 Grenoble, France.
    Background: Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal adverse effect of neuroleptic drugs. It is commonly characterized by muscular rigidity, fever, altered mental status, and autonomic dysfunction. Emerging of NMS is possible with all neuroleptics, classic and atypical. Read More
    [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].
    Encephale 2008 Dec 2;34(6):618-24. Epub 2008 Apr 2.
    Background: Neuroleptic malignant syndrome (NMS) is an uncommon, but potentially life threatening complication of neuroleptic drugs. In 1960, Delay et al. [Ann Med Psychol 118 (1960) 145-152] described the "syndrome akinétique hypertonique"(hypertonic akinetic syndrome) and its cardinal symptoms: hyperthermia, extrapyramidal symptoms, altered mental status and autonomic dysfunctions. Read More
    [Malignant neuroleptic syndrome. A review of epidemiology, risk factors, diagnosis, differential diagnosis and pathogenesis of MNS].
    Ugeskr Laeger 2000 Mar;162(10):1366-70
    Aalborg Psykiatriske Sygehus, Retspsykiatrisk Afdeling E.
    Neuroleptic malignant syndrome (NMS) is a rare, potentially life-threatening disorder that results from the use of neuroleptics. NMS was first recognised as a complication of dopamine receptor antagonists characterized by extrapyramidal disturbances, hyperthermia, muscle rigidity, autonomic instability, mental status changes and elevated serum creatine kinase levels. Concepts of NMS have changed because medications other than classic neuroleptic drugs have been implicated as triggering agents. Read More